Overexpression of miR-222-3p Promotes the Proliferation and Inhibits the Apoptosis of Diffuse Large B-Cell Lymphoma Cells via Suppressing PPP2R2A

Shanshan Sun, MM¹, Hui Wang, BM², and Mingyou Ji, BM²

Abstract

Purpose: This study aimed to investigate the effects of microRNA-222-3p on activated B cell-like-type diffuse large B-cell lymphoma cells and the regulatory relationship between microRNA-222-3p and phosphatase 2 regulatory subunit B alpha.

Method: The expression of microRNA-222-3p was detected in activated B cell-like-type diffuse large B-cell lymphoma tissues and cells by quantitative reverse transcription polymerase chain reaction. The regulatory effects of microRNA-222-3p on the proliferation, invasion, and apoptosis of activated B cell-like-type diffuse large B-cell lymphoma cells were analyzed by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT), colony formation, flow cytometry, and Transwell assay. The regulatory relationship between microRNA-222-3p and phosphatase 2 regulatory subunit B alpha was determined by luciferase reporter gene and RNA pull-down assay. In addition, the effects of microRNA-222-3p on tumor growth were further analyzed in mice.

Results: MicroRNA-222-3p and phosphatase 2 regulatory subunit B alpha were significantly up- and downregulated in activated B cell-like-type diffuse large B-cell lymphoma tissues and cells, respectively. Phosphatase 2 regulatory subunit B alpha was a target of microRNA-222-3p. MicroRNA-222-3p promoted the proliferation and invasion and inhibited the apoptosis of activated B cell-like-type diffuse large B-cell lymphoma cells. Phosphatase 2 regulatory subunit B alpha reversed the tumor-promoting effects of microRNA-222-3p on activated B cell-like-type diffuse large B-cell lymphoma cells. In addition, microRNA-222-3p promoted the tumor growth in mice and downregulated phosphatase 2 regulatory subunit B alpha in tumor tissues.

Conclusion: MicroRNA-222-3p promoted the proliferation and invasion and inhibited the apoptosis of activated B cell-like-type diffuse large B-cell lymphoma cells through suppressing phosphatase 2 regulatory subunit B alpha expression.

Keywords: diffuse large B-cell lymphoma, miR-222-3p, PPP2R2A, proliferation, invasion, apoptosis

Abbreviations

ABC, activated B cell-like; DLBCL, diffuse large B-cell lymphoma; FBS, fetal bovine serum; GCB, germinal central B cell; inhibitors NC, miR-222-3p inhibitors negative control; IPI, International Prognostic Index; miRs, microRNAs; miR-222-3p, microRNA-222-3p; mimics NC, miR-222-3p mimics negative control; pcDNA3.1-NC, pcDNA3.1 negative control; OS, overall survival; PBS, phosphate-buffered saline; P/S, penicillin–streptomycin; PPP2R2A, protein phosphatase 2 regulatory subunit B alpha; PPP2R2A-WT, PPP2R2A wild-type; PPP2R2A-MUT, PPP2R2A mutant; qRT-PCR, quantitative reverse transcription polymerase chain reaction; 3'-UTR, 3'-untranslated region

Received: June 3, 2019; Revised: September 11, 2019; Accepted: October 21, 2019.

Introduction

Diffuse large B-cell lymphoma (DLBCL) is a highly invasive non-Hodgkin lymphoma, accounting for 30% to 40% of non-Hodgkin lymphoma cases.¹ The initial response rate of DLBCL is about 90%, but the 5-year recurrence rate is as high as 40%.² Drug resistance during treatment also greatly plagues clinicians.
and patients. About 30% of patients with DLBCL die of relapse or drug resistance. The pathogenesis of DLBCL remains unclear, which hinders further progress in the treatment of DLBCL.

In recent years, some molecular pathogenesis of DLBCL has been preliminarily discovered. In addition to coding genes, some noncoding genes, especially microRNAs (miRs), are considered to be one of the most important targets for regulating DLBCL development. MicroRNAs are key regulators of tumorogenesis and development during the last decade. The important role of these miRs in the progression of DLBCL has also been mentioned in previous studies. As a member of miRs, miR-222 has been proved to be involved in the progression of multiple cancers, such as breast cancer, nasopharyngeal carcinoma, and colorectal cancer. A previous study indicated that intestinal inflammation can be aggravated by upregulation of miR-222 during the disease progression. Importantly, miR-222 is closely related to the development of DLBCL. Based on the expression profile of miRs, it indicated that miR-222 is a potential biomarker for Epstein-Barr virus-positive DLBCL. In fact, the biological function of miR-222 in disease is usually achieved by targeting certain genes. Protein phosphatase 2 regulatory subunit B alpha (PPP2R2A) belongs to protein phosphatase 2 regulatory subunit B family and participates in the negative control of cell growth and division. Dong et al showed that miR-222 is overexpressed in biliary atresia, and silencing of miR-222 inhibits the proliferation of LX-2 cells (human hepatic stellate cell line) by targeting PPP2R2A. Zeng et al showed that overexpression of miR-222 attenuates cisplatin-induced autophagy in bladder cancer cells by targeting PPP2R2A. In addition, PPP2R2A has been proved to be a tumor suppressor that can inhibit the proliferation of a variety of cancer cells, such as non-small cell lung cancer cells, prostate cancer cells, and colorectal cancer cells. However, the specific role of miR-222 on DLBCL and the relationship between miR-222 and PPP2R2A remain unclear.

Activated B-cell-like (ABC-type) DLBCL, characterized by high-level constitutive nuclear factor kappa-B activation, is an important subtype of DLBCL with poor prognosis and treatment response. In this study, the regulatory effects of miR-222 on the proliferation, migration, invasion, and apoptosis of ABC-type DLBCL cells were analyzed. The regulatory relationship between miR-222-3p and PPP2R2A in ABC-type DLBCL cells was further determined. Our findings may provide a novel therapeutic target for ABC-type DLBCL and a new insight into the underlying mechanisms.

Materials and Methods

Patients and Sample Collection

A total of 74 cases with initial diagnosis of ABC-type DLBCL were screened from our hospital from February 2016 to November 2018. Activated B-cell-like-type DLBCL was diagnosed histopathologically according to Hans-type principles. These patients had not received chemotherapy, radiation, or other biological treatments previously. Other types of lymphoma and DLBCL combined with other diseases were excluded. A total of 26 patients with pathological diagnosis of reactive lymphoid hyperplasia were selected as the control. The specimens were excised during surgery and then preserved in liquid nitrogen at 80°C until RNA was extracted. Overall survival (OS) was defined from registration to death. This study was approved by the ethics committee of our hospital. All patients signed a written informed consent.

Cell Culture

Human normal B-cell immortalized cell line (HMy2.CIR), DLBCL cell line, germinal central B-cell (GCB)-like OCI-Ly19 and SU-DHL-4, and ABC-like OCI-LY10 and U2932 were purchased from Shanghai Cell Bank of the Chinese Academy of Sciences. HMy2.CIR was cultured in Iscove’s modified dulbecco’s medium (IMDM) (Gibco, Carlsbad, CA, USA) containing 10% fetal bovine serum (FBS), and 1% penicillin–streptomycin (P/S). U2932 and SU-DHL-4 were cultured in RPMI 1640 medium (Gibco) containing 10% FBS and 1% P/S. OCI-LY10 and OCI-Ly19 were cultured in IMDM (Gibco) containing 20% FBS and 1% P/S. All cells were maintained in a humid incubator with 5% CO2 at 37°C.

Cell Transfection and Grouping

OCI-LY10 and U2932 cells were seeded into 6-well plates (5 × 105 cells/well). The miR-222-3p mimics, miR-222-3p inhibitors, miR-222-3p mimics negative control (mimics NC), miR-222-3p inhibitors negative control (inhibitors NC), pcDNA3.1 negative control (pcDNA3.1-NC), pcDNA3.1-PPP2R2A (Jima, Shanghai, China) (15 μL for each) were dissolved in 250 mL medium and mixed uniformly to obtain A solution, respectively. Meanwhile, 5 mL EntransterTM-R transfection reagent (Engreen Biosystem) was mixed with 250 mL culture medium uniformly to obtain B liquid. The solution A and B were then mixed uniformly and incubated in an incubator for 48 hours (37°C, 5% CO2). Cells were divided into miR-222-3p mimics group, mimics NC group, miR-222-3p inhibitors group and inhibitors NC group, mimics NC + pcDNA3.1-NC group, miR-222-3p mimics + pcDNA3.1-NC group, mimics NC + pcDNA3.1-PPP2R2A group, and miR-222-3p mimics + pcDNA3.1-PPP2R2A group. Cells without transfection were considered as blank group.

Quantitative Reverse Transcription Polymerase Chain Reaction

The expression of miR-222-3p was detected by quantitative reverse transcription polymerase chain reaction (qRT-PCR). Simply total RNA was extracted form cells using TRIzol and then reverse transcribed using Reverse Transcription Kit (Invitrogen, San Diego, California) in accordance with the manufacturer’s instructions. Quantitative reverse transcription
polymerase chain reaction was performed on ABI PRISM® 7300 (Applied Biosystems, Foster City, California). The PCR program included 40 cycles of 95°C for 3 minutes, 95°C for 10 seconds, and 55°C for 30 seconds. The data were analyzed by the 2−ΔΔCt method. All primers were designed and synthesized by Biotechnology Bioengineering Co, Ltd (Shanghai, China), and the primer sequences are listed in Table 1.

**Luciferase Reporter Gene Assay**

The target site of miR-222-3p to PPP2R2A was predicted by TargetScan (http://www.targetscan.org/). The sequence fragments of PPP2R2A wild-type (PPP2R2A-WT) and mutant (PPP2R2A-MUT) were synthesized and cloned into pGL3 luciferase vector (Promega, Madison, WI, USA). EHK-293T cells (American type culture collection) were seeded into 24-well plates (5×10⁵ cells/well) and cotransformed with PPP2R2A-WT (or PPP2R2A-MUT) and miR-222-3p mimic (or mimic NC) using Lipofectamine 2000 (Thermo Fisher Scientific). Biotin RNA labeling cocktail (Roche Diagnostics, Indianapolis, Indiana) was used to synthesize Bio-miR-222-3p-Wt, Bio-miR-222-3p-Mut, and Bio-miR-NC. Then 50 pmol biotinylated RNA was mixed with 200 μg cell lysate (OCl-LY10 and U2932) and incubated with 50 μl streptavidin agarose (Invitrogen, Carlsbad, California) for 1 hour at 4°C. The expression of PPP2R2A was measured by qRT-qPCR.

**RNA Pull-Down Assay**

MiR-222-3p-Wt, miR-222-3p-Mut, and miR-NC were transcribed using TranscriptAid T7 High Yield Transcription Kit (Thermo Fisher Scientific). Biotin RNA labeling cocktail (Roche Diagnostics, Indianapolis, Indiana) was used to synthesize Bio-miR-222-3p-Wt, Bio-miR-222-3p-Mut, and Bio-miR-NC. Then 50 pmol biotinylated RNA was mixed with 200 μg cell lysate (OCl-LY10 and U2932) and incubated with 50 μl streptavidin agarose (Invitrogen, Carlsbad, California) for 1 hour at 4°C. The expression of PPP2R2A was measured by qRT-qPCR.

**MTT Assay**

The transfected cells were seeded in 96-well plates (6×10³ cells/well) and cultured in an incubator (37°C, 5% CO₂) for 24 to 72 hours. 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) (5 mg/mL) was then added into each well at a volume of 20 μL. After 4 hours of incubation, 150 μL dimethyl sulfoxide was added into each well to promote crystallization dissolution. The absorbance values at 0, 24, 48, and 72 hours were measured, and MTT plot was drawn (y-axis: absorbance value; x-axis: interval time). The experiment was repeated 3 times.

** Colony Formation Assay**

The transfected cells were washed with phosphate-buffered saline (PBS), digested with 1% trypsin, and seeded in 6-well plates (300 cells/well). Two weeks later, cells were washed with PBS twice, fixed with 4% paraformaldehyde, and then stained with Swiss-Giema for 15 minutes. Positive stained colonies were observed under an inverted phase contrast microscope (Olympus Ckx53, Tokyo, Japan) and counted automatically by using ImageJ (version 1.48) software. Cell colony formation rate was calculated as (colony number/total number of seeded cells) × 100%.

**Flow Cytometry**

The apoptosis of transfected cells was measured by Annexin V/Fluorescein isothiocyanate (FITC) apoptosis detection kit (Kaiji Biotechnology, Nanjing, China). A mixture of 5 μL PI and 5 μL Annexin V/FITC was added to cells and incubated for 15 minutes. The apoptotic rate was detected on flow cytometry.

**Transwell Assay**

The invasion of transfected cells was measured by Transwell chamber (Corning, New York). Simply cells were adjusted to 2×10⁵/mL in serum-free RPMI-1640 medium, and 200 μL cells were added to the upper chamber; 400 μL RPMI-1640 medium containing 20% FBS was added to the lower chamber (24-well plate). After 48 hours of culturing (37°C, 5% CO₂), the medium was removed. The left cells were washed twice with PBS, fixed with 4% paraformaldehyde for 30 minutes, and stained with crystal violet for 20 minutes. Positive stained cells were observed under microscope (×200), and the number of cells passing through the membrane was counted in 5 random fields.

**Western Blot Analysis**

Western blot was used to measure the expression of proteins. Simply 50 μg total protein was extracted by lysis buffer and quantified with a bicinchoninic acid assay kit (Kaiji Biotech, Nanjing, China). The samples were subjected to 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis and then transferred onto polyvinylidene fluoride membrane. The membrane was then blocked with 5% skim milk in Tris-buffered saline with Tween solution. Subsequently, the membrane was sequentially incubated with primary antibodies (Rabbit anti-human Bcl-2, Bax, PPP2R2A, 1:2000; Abcam, Cambridge, United Kingdom) and secondary antibody (bs-0295G-HRP, 1:5000; Beijing Biosynthesis Biotechnology, Beijing, China). Finally, the bands were visualized by Enhanced

---

**Table 1. The Primer Sequences.**

| Name of Primer | Sequences |
|----------------|-----------|
| miR-222-3p-F   | ACACCTCCAGCTGGAGCTACATCTGGCTACTG |
| miR-222-3p-R   | CTCAACTGGTGTGCTAGGGA |
| U6-F           | CTGCGTTCGGCAGCA |
| U6-R           | AAGCGTTCAGAATTTGCGT |
| PPP2R2A-F      | AAAGGAACATTCCGCTATGTTG |
| PPP2R2A-R      | AAAATGACCTGTTACTGGGATC |
| GAPDH-F        | GACAGTGCAAGGCTGAGAAGT |
| GAPDH-R        | ATGGTGTTGAAGACGCGAT |

Abbreviations: GAPDH, glyceraldehyde-3-phosphate dehydrogenase; miR, micro RNA; PPP2R2A, protein phosphatase 2 regulatory subunit B alpha.
Chemiluminescence Plus, and the integrated optical density was measured by software Lab Works version 4.5.

Tumor Growth Assay

A total of 18 SPF BALB/c nude mice (4 weeks old) were purchased from SLACL Laboratory Animal Center (Shanghai, China). Then 0.1 mL OCI-LY10 cells (1.0 × 10⁷/mL; blank, miR-222-3p mimics, mimics NC) were subcutaneously injected into the flank of mice (6 mice in each group). The tumor volume was measured every 7 days after the injection according to the formula of (L × W²)/2 (where L represented the length and W represented the width). After the injection for 56 days, mice were anesthetized with CO₂ and killed. Tumor tissues were collected for further analysis. All animal experiments were approved by Institutional Animal Care and Use Committee.

Statistical Analysis

All statistical analyses were performed using SPSS version 21.0 software. The results were presented as mean ± standard deviation. The data of 2 groups were analyzed by the Student t test. The data of more than 2 groups were analyzed by one-way analysis of variance, followed by Tukey post hoc test. Kaplan-Meier survival analysis was performed to assess the correlation between miR-222-3p and survival of patients. Pearson correlation test was used to assess the correlation between PPP2R2A and miR-222-3p expression. P < .05 was considered to be statistically significant.

Results

The Expression of MiR-222-3p and PPP2R2A in DLBCL

The expression of miR-222-3p in ABC-type patients with DLBCL was detected by qRT-PCR. The result showed that miR-222-3p expression in patients with DLBCL was higher than that in the control group (Figure 1A). Kaplan-Meier analysis showed that the OS was significantly higher in patients with low miR-222-3p expression than in patients with high miR-222-3p expression (Figure 1B). The expression of miR-222-3p in DLBCL cell lines (OCI-LY19, SU-DHL-4, OCI-LY10, and U2932) was higher than that in HM2.CIR (Figure 1C). Since the miR-222-3p expression in ABC-type DLBCL was higher than that of GCB type, ABC-type DLBCL cell lines OCI-LY10 and U2932 were selected for further investigation. Furthermore, the relationship between the expression of miR-222-3p and the clinicopathological parameters of ABC-type DLBCL was listed in Table 2. The result showed that compared with patients of III/IV
stage, extranodal invasion, and International Prognostic Index (IPI) score of 3 to 5, the expression of miR-222-3p was significantly lower in patients of I/II stage, no extranodal invasion, and IPI score of 0 to 2, respectively (all $P < .05$).

**MiR-222-3p Promoted the Proliferation and Invasion of ABC-Type DLBCL Cells**

The expression of miR-222-3p in OCI-LY10 and U2932 cells was significantly higher in miR-222-3p mimics group than in mimics NC group (all $P < .05$; Figure 2A). Meanwhile, the expression of miR-222-3p in OCI-LY10 and U2932 cells was significantly lower in miR-222-3p inhibitors group than in inhibitors NC group (all $P < .05$).

**Figure 2.** Micro RNA-222-3p promotes the proliferation and invasion of activated B cell-like (ABC)-type diffuse large B-cell lymphoma (DLBCL) cells. A, The expression of miR-222-3p in miR-222-3p mimics or negative control (NC)-transfected OCI-LY10 and U2932 cells detected by quantitative reverse transcription polymerase chain reaction (qRT-PCR). B, The expression of miR-222-3p in miR-222-3p inhibitors or NC-transfected OCI-LY10 and U2932 cells detected by qRT-PCR. C, The proliferation of transfected OCI-LY10 and U2932 cells detected by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) assay. D, The proliferation of transfected OCI-LY10 and U2932 cells detected by colony formation assay. E, The invasion of transfected OCI-LY10 and U2932 cells detected by transwell invasion assay. Compared with blank and mimics NC, *$P < .05$; compared with Blank and inhibitors NC, $^\#P < .05$. Data were expressed as mean ± standard deviation. All experiments were repeated 3 times.
Meanwhile, the number of invasive cells in miR-222-3p inhibitors group was less than that in the inhibitors NC group (all $P < .05$; Figure 2E).

**MiR-222-3p Inhibited the Apoptosis of ABC-Type DLBCL Cells**

Flow cytometry showed that the apoptotic rate was lower in the miR-222-3p mimics group than in the mimics-NC group (all $P < .05$) and was significantly higher in the miR-222-3p inhibitors group than in the inhibitors-NC group (all $P < .05$; Figure 3A).

Western blot was used to detect the expression of Bcl-2 and Bax in transfected OCI-LY10 and U2932 cells. The results showed that Bcl-2 and Bax were significantly upregulated in miR-222-3p mimics group compared with that in the mimics NC group, respectively (all $P < .05$). Meanwhile, Bcl-2 and Bax were significantly downregulated and upregulated in the mi-222-3p inhibitors group compared with that in the inhibitors NC group, respectively (all $P < .05$; Figure 3B).

**Protein Phosphatase 2 Regulatory Subunit B Alpha Was a Target Gene of MiR-222-3p**

TargetScan showed that miR-222-3p had a binding site at 3'-untranslated region (3'-UTR) of PPP2R2A (Figure 4A). The luciferase activity was significantly lower in the miR-222-3p mimics + PPP2R2A WT group than other groups ($P < .05$; Figure 4B). RNA pull-down assay further illustrated that miR-222-3p bind to PPP2R2A (Figure 4C). The transfection of miR-222-3p mimic and pcDNA3.1-PPP2R2A decreased and the expression of PPP2R2A increased in OCI-LY10 and U2932 cell at both the mRNA and protein levels, respectively. The cotransfection of miR-222-3p mimics and pcDNA3.
Figure 4. Protein phosphatase 2 regulatory subunit B alpha (PPP2R2A) is a target gene of miR-222-3p. A, The binding site of miR-222-3p at 3' untranslated region (3'UTR) PPP2R2A predicted by TargetScan. B, The binding ability between PPP2R2A and miR-222-3p confirmed by dual-luciferase reporter gene assay; compared with the cotransfection of miR-222-3p mimics and PPP2R2A-MUT, *P < .05. C, The binding ability between PPP2R2A and miR-222-3p confirmed by RNA pull-down assay; compared with Bio-NC group, *P < .05. D, The expression of PPP2R2A in miR-222-3p mimics or pcDNA3.1-PPP2R2A-transfected OCI-LY10 and U2932 cells detected by quantitative reverse transcription polymerase chain reaction (qRT-PCR). E, The expression of PPP2R2A detected by Western blot; compared with blank or mimics negative
1-PPP2R2A reversed the downregulation effect of miR-222-3p mimics on PPP2R2A expression (Figure 4D and E). In addition, the expression of PPP2R2A in ABC-type patients with DLBCL was lower than that in the control group (Figure 4F). There was a negative correlation between miR-222-3p and PPP2R2A expression in ABC-type patients with DLBCL \((r = -0.6862; \ P < .0001;\) Figure 4G). The expression of PPP2R2A in DLBCL cell lines (OCI-LY19, SU-DHL-4, OCI-LY10, and U2932) was lower than that in HMy2.CIR (Figure 4H).

**Overexpression of PPP2R2A Reversed the Effects of MiR-222-3p on the Proliferation and Apoptosis of ABC-Type DLBCL Cells**

Compared with the mimics NC + pcDNA3.1-NC group, the OD490 was significantly increased in the miR-222-3p mimics + pcDNA3.1-NC group and decreased in the mimics NC + pcDNA3.1-PPP2R2A group \((P < .05;\) Figure 5A). Compared with the mimics NC + pcDNA3.1-NC group, the apoptotic rate was significantly decreased in the mimics NC + pcDNA3.1-NC group and increased in the mimics NC + pcDNA3.1-PPP2R2A group (Figure 5B). In addition, compared with the mimics NC + pcDNA3.1-NC group, Bcl-2 and Bax were significantly up- and downregulated in the miR-222-3p mimics + pcDNA3.1-NC group, respectively. Compared with the mimics NC + pcDNA3.1-NC group, Bcl-2 and Bax were significantly down- and upregulated in mimics NC + pcDNA3.1-PPP2R2A group, respectively (Figure 5C).

**Mi-222-3p Mimics Promoted the Tumor Growth in Nude Mice**

The tumor volume was larger in the miR-222-3p mimics group than in the mimics NC group at day 21, 35, 49, and 56 post-injection (Figure 6A). In addition, qRT-PCR showed that the expression of PPP2R2A in tumor tissues was lower in the miR-222-3p mimics group than in the mimics NC group at both the mRNA and protein levels \((P < .05;\) Figure 6B and C).

**Discussion**

Diffuse large B-cell lymphoma is a common malignant tumor with strong invasive ability.\(^{24}\) Although miR-222 has been proved to be related to the development of DLBCL,\(^{15}\) the specific action mechanism of miR-222 in DLBCL progression remains unclear. In this study, miR-222-3p and PPP2R2A were significantly upregulated and downregulated in ABC-type DLBCL tissues and cells compared with the control group, respectively. In addition, luciferase reporter gene and RNA pull-down assay showed that miR-222-3p had a binding site at 3'-UTR of PPP2R2A. Furthermore, MTT, colony formation, flow cytometry, and Transwell assay showed that miR-222-3p promoted the proliferation and invasion and inhibited the apoptosis of ABC-type DLBCL cells. Finally, the mice experiment showed that miR-222-3p mimics promoted the tumor growth in mice and inhibited PPP2R2A expression in tumor tissues.

MiR-222 is upregulated in various diseases and considered as a therapeutic target.\(^{25,26}\) A previous study showed that miR-222 is overexpressed in both patients with *Helicobacter pylori*-infected and noninfected gastric cancer.\(^{28}\) A miRs signature profile proved that miR-222 is upregulated in DLBCL.\(^{29}\) Garofalo et al indicated that the downregulation of miR-222 contributes to the enhanced tumorigenicity.\(^{30}\) Gan et al showed that the downregulation of miR-222 enhances the sensitivity of breast cancer cells to tamoxifen.\(^{31}\) In fact, miR-222 overexpression can promote the proliferation of tumor cells via targeting specific genes,\(^{32}\) like PPP2R2A.\(^{17}\) Protein phosphatase 2 regulatory subunit B alpha has been proved to be a tumor suppressor in a variety of cancers.\(^{18,20}\) Beca et al showed that low expression of PPP2R2A is significantly associated with poor disease-free survival and OS in patients with breast cancer.\(^{33}\) Zhao et al showed that early hemizygous loss of PPP2R2A facilitates effective mitotic progression of prostate cancer cells.\(^{19}\) In addition, Lian et al indicated that overexpression of miR-892a promotes the proliferation and colony formation of colorectal cancer cells through suppressing PPP2R2A.\(^{20}\) Zhang et al indicated that the upregulation of miR-614 promotes the proliferation and inhibits the apoptosis of ovarian cancer cells by suppressing PPP2R2A.\(^{34}\) The above findings illustrate the tumor-suppressing role of PPP2R2A on tumor progression. In the current study, miR-222-3p and PPP2R2A were significantly up- and downregulated in ABC-type DLBCL tissues and cells, respectively. Meanwhile, luciferase reporter gene and RNA pull-down assay showed that 3'-UTR PPP2R2A carried the binding site of miR-222-3p. Therefore, we speculate that the upregulation of miR-222-3p may be involved in the progression of ABC-type DLBCL by suppressing PPP2R2A expression.

The expression of miRs is widely believed to be pathogenetically involved in DLBCL.\(^{35,36}\) MiR-222 is an important miR, which can affect multiple tumor cell processes, including proliferation, differentiation, apoptosis, invasion, and metastasis.\(^{37}\) A previous study showed that the downregulation of miR-222 inhibits the proliferation and migration of prostate cancer cells.\(^{38}\) Liu et al indicated that miR-222 promotes the proliferation, migration, and invasion and inhibits the apoptosis of liver cancer cells.\(^{37}\) The inhibition of miR-222-3p results in a
Figure 5. Overexpression of protein phosphatase 2 regulatory subunit B alpha (PPP2R2A) reversed the effect of miR-222-3p on the proliferation and apoptosis of activated B cell-like (ABC)-type diffuse large B-cell lymphoma (DLBCL) cells. A, The proliferation of miR-222-3p mimics or pcDNA3.1-PPP2R2A-transfected OCI-LY10 and U2932 cells detected by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) assay. B, The apoptosis of transfected OCI-LY10 and U2932 cells detected by flow cytometry. C, The expression of B-cell lymphoma-2 (Bcl-2) and Bcl-2 associated X (Bax) in transfected OCI-LY10 and U2932 cells detected by Western blot. Compared with the blank or mimics negative control (NC) + pcDNA3.1-NC group, *P < .05. Data were expressed as mean ± standard deviation. All experiments were repeated 3 times.
decrease in the activity of cell proliferation and invasion. In addition, miR-222 induces the apoptosis of gastrointestinal stromal tumor cells, prostate cancer cells, and neck squamous cell carcinoma cells. In this study, the proliferation and invasion of ABC-type DLBCL cells were promoted and the apoptosis was inhibited in the miR-222-3p mimics group compared with the mimics NC group. We speculate that miR-222-3p can promote the proliferation and invasion and inhibit the apoptosis of ABC-type DLBCL cells. However, the current research also has some limitations, such as the regulatory role of miR-222-3p and PPP2R2A on GCB-type DLBCL cells and the specific action mechanism of PPP2R2A.

Conclusion

In conclusion, the upregulation of miR-222-3p played an important role in the progression of ABC-type DLBCL. MiR-222-3p promoted the proliferation and invasion and inhibited the apoptosis of ABC-type DLBCL cells by suppressing PPP2R2A expression.

Authors’ Note

This study was conducted after obtaining Shouguang People’s Hospital of Shandong Province’s ethical committee approval and written informed consent from the patients. This study was approved by the Ethical Committee of Shouguang People’s Hospital of Shandong Province, and written informed consent was obtained from patients (No. 201812201901).

Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iD
Shanshan Sun https://orcid.org/0000-0002-9175-083X

References
1. Chaganti S, Illidge T, Barrington S, et al. Guidelines for the management of diffuse large B-cell lymphoma. Br J Haematol. 2016;174(1):43-56.
2. Mathur R, Sehgal L, Havranek O, et al. Inhibition of demethylase KDM6B sensitizes diffuse large B-cell lymphoma to chemotherapeutic drugs. Haematologica. 2017;102(2):373-380.
3. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010:
a systematic analysis for the Global Burden of Disease Study 2010. *Lancet*. 2012;380(9859):2163-2169.

4. Pasqualucci L, Ott G. Pathology and molecular pathogenesis of DLBCL and related entities. In: Lenz G, Salles G, eds. *Aggressive Lymphomas*. Cham, Switzerland: Springer; 2019:41-73.

5. Hershkovitzrokah O, Geva P, Salmondovitch M, Shlipberg O, Libermanarono S. Network analysis of microRNAs, genes and their regulation in diffuse and follicular B-cell lymphomas. *Oncotarget*. 2018;9(8):7928-7941.

6. Waters PS, Dwyer RM, Wall D, Mcdermott AM, Newell J, Kerin MJ. Relationship between circulating and tissue MiRNAs in a murine model of breast cancer. *PLoS One*. 2012;48(11):e199-200.

7. Huang X, Shen Y, Liu M, et al. Quantitative proteomics reveals that miR-155 regulates the PI3K-AKT pathway in diffuse large B-cell lymphoma. *Am J Pathol*. 2012;181(1):26-33.

8. Kluiver J, Poppema S, de Jong D, et al. BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. *J Pathol*. 2010;207(2):243-249.

9. Han SH, Kim HJ, Gwak JM, Kim M, Chung YR, Park SY. MicroRNA-222 expression as a predictive marker for tumor progression in hormone receptor-positive breast cancer. *J Breast Can*. 2017;20(1):35-44.

10. Liu S, Sun X, Wang M, et al. A microRNA 221- and 222-mediated feedback loop maintains constitutive activity of NFkB and STAT3 in colorectal cancer cells. *Gastroenterology*. 2014;147(4):847-859.

11. Wu W, Chen X, Yu S, Wang R, Zhao R, Du C. MicroRNA-222 promotes tumor growth and confers radioresistance in nasopharyngeal carcinoma by targeting PTEN. *Mol Med Rep*. 2017;17(1):1305-1310.

12. Wang Z, Liu J, Liang P, Bo J, Ye C. Tu1828 loss of syndecan-1 by upregulation of microRNA-221/222 in response to lipopolysaccharide aggravates intestinal inflammation. *Gastroenterology*. 2015;148(4):S913-S913.

13. Mazanmameczar K, Gartenhaus RB. Role of microRNA deregulation in the pathogenesis of diffuse large B-cell lymphoma (DLBCL). *Leuk Res*. 2013;37(11):1420-1428.

14. Andrade TAD, Evangelista AF, Borges NM, et al. Micro-RNA expression profile reveals MiR-222 as a potential biomarker for EBV-positive diffuse large B-cell lymphoma. *Blood*. 2013;122(21):4269.

15. Zeng LP, Hu ZM, Li K, Xia K. MiR-222 attenuates cisplatin-induced cell death by targeting the PPP2R2A/Akt/mTOR Axis in bladder cancer cells. *J Cell Mol Med*. 2016;20(3):559-567.

16. Janssens V, Goris J, Van HC. PP2A: the expected tumor suppressor. *Curr Opin Genet Dev*. 2005;15(1):34-41.

17. Dong R, Zheng Y, Chen G, Zhao R, Zhou Z, Zheng S. MiR-222 overexpression may contribute to liver fibrosis in biliary atresia by targeting PPP2R2A. *J Pediat Gastroenterol Nut*. 2015;60(1):84-90.

18. Shen S, Yue H, Li Y, et al. Upregulation of mir-136 in human non-small cell lung cancer cells promotes Erk1/2 activation by targeting PPP2R2A. *Tumour Biol*. 2014;35(1):631-640.

19. Zhao Z, Kurimchak A, Adayemi M, Woodruff P, Kolenko V, Graña X. Analysis of the tumor suppressor function of B55alpha, the PP2A regulatory subunit encoded by PPP2R2A, in prostate cancer cells. *Cancer Res*. 2016;76(14 suppl):3662-3662.

20. Liang WL, Cao J, Xu B, et al. MiR-892a regulated PPP2R2A expression and promoted cell proliferation of human colorectal cancer cells. *Biomed Pharmacother*. 2015;72:119-124.

21. Lin XY, Huang XL, Sarthy A, et al. ABBV-075 exhibits robust in vitro and in vivo activities against the ABC and GCB subtypes of DLBCL. *Cancer Res*. 2016;76(14 suppl):4706-4706.

22. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. *Blood*. 2015;103(1):275-282.

23. Livak KJST. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. *Methods*. 2001;25(4):402-408.

24. Mundi JP, Leger M, Terushkin V, et al. Diffuse large B-cell lymphoma. *Dermatol Online J*. 2017;115(21):4980-4989.

25. Sredni ST, Ronaldo MDF, Costa FF, et al. Upregulation of mir-221 and mir-222 in atypical teratoid/rhabdoid tumors: potential therapeutic targets. *Childs Nerv Syst*. 2010;26(3):279-283.

26. Ogawa T, Enomoto M, Fujii H, et al. MicroRNA-221/222 upregulation indicates the activation of stellate cells and the progression of liver fibrosis. *Gut*. 2012;61(11):1600-1609.

27. Elatta ASA, Ali YBM, Bassouyini IH, Talaat RM. Upregulation of miR-221/222 expression in rheumatoid arthritis (RA) patients: correlation with disease activity. *Clin Exp Med*. 2018;19(1):47-53.

28. Noormohammad M, Sadeghi S, Tabatabaeian H, et al. Upregulation of miR-222 in both *Helicobacter pylori*-infected and noninfected gastric cancer patients. *J Genet*. 2016;95(4):991-995.

29. Andrade TAD, Adriane Feijo E, Campos AHF, et al. A microRNA signature profile in EBV + diffuse large B-cell lymphoma of the elderly. *Oncotarget*. 2014;5(23):11813-11826.

30. Garofalo M, Di LG, Romano G, et al. miR-221/222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. *Cancer Cell*. 2009;16(6):498-509.

31. Han R, Yang Y, Yang X, Zhao L, Lu J, Meng QH. Downregulation of miR-221/222 enhances sensitivity of breast cancer cells to tamoxifen through upregulation of TIMP3. *Cancer Gene Ther*. 2014;21(7):290-296.

32. Yang YF, Wang F, Xiao JJ, et al. MiR-222 overexpression promotes proliferation of human hepatocellular carcinoma HepG2 cells by downregulating p27. *Int J Clin Exp Med*. 2014;7(4):893-902.

33. Beca F, Pereira M, Cameselle-Teijeiro JF, Martins D, Schmitt F, Altered PPP2R2A and cyclin D1 expression defines a subgroup of aggressive luminal-like breast cancer. *BMC Cancer*. 2015;15(1):285.

34. Zhang J, Gao D, Zhang H. Upregulation of miR-614 promotes proliferation and inhibits apoptosis in ovarian cancer by suppressing PPP2R2A expression. *Mol Med Rep*. 2018;17(5):6285-6292.

35. Keister LA, Zhang Y, Xu GX, et al. Regulation of microRNA on proliferation and differentiation of tumour cells. *Science Technol Rev*. 2009;27(2):94-98.

36. Koen S, Qin Y, Leung WY, et al. MicroRNA profiling of primary cutaneous large B-cell lymphomas. *PLoS One*. 2013;8(12):e82471.
37. Liu ZC, Sun JW, Liu B, Zhao MJ, Xing ET, Dang CS. miRNA-222 promotes liver cancer cell proliferation, migration and invasion and inhibits apoptosis by targeting BBC3. *Int J Mol Med*. 2018;42(1):141-148.

38. Yang X, Yang Y, Gan R, et al. Down-regulation of mir-221 and mir-222 restrain prostate cancer cell proliferation and migration that is partly mediated by activation of SIRT1. *PLoS One*. 2014;9(6):289-293.

39. Liu B, Che Q, Qiu H, et al. Elevated miR-222-3p promotes proliferation and invasion of endometrial carcinoma via targeting ERα. *PLoS One*. 2014;9(1):e87563.

40. Ihle MA, Trautmann M, Kuenstlinger H, et al. miRNA-221 and miRNA-222 induce apoptosis via the KIT/AKT signalling pathway in gastrointestinal stromal tumours. *Mol Oncol*. 2015;9(7):1421-1433.

41. Liu X, Jiang L, Wang A, Yu J, Shi F, Zhou X. MicroRNA-138 suppresses invasion and promotes apoptosis in head and neck squamous cell carcinoma cell lines. *Cancer Lett*. 2009;286(2):217-222.

42. Wang L, Liu C, Li C, et al. Effects of microRNA-221/222 on cell proliferation and apoptosis in prostate cancer cells. *Gene*. 2015;572(2):252-258.